Margit Kunz – Chief Executive Director, AHK Debelux
Germany and Belgium have long held an important trading relationship, says Margit Kunz of AHK Debelux, the German chamber of commerce in Belgium and Luxembourg. She outlines some of the…
Address: Avenue Ariane 16 1200 Brussels Belgium
Tel: +32 (0)2 773 33 11
Web: http://www.boehringer-ingelheim.be/
The Boehringer Ingelheim group
Our group, established in Ingelheim (Germany), has 137 subsidiaries across 47 countries and approximately 41,500 employees, of which nearly 5,000 are active in research and development.
Since its foundation in 1885, the group is still wholly owned by the founding family and focused on researching, developing and producing and marketing of new products with high added value for medical use, also in veterinary medicine.
In Belgium and Luxembourg Boehringer Ingelheim employs over 250 staff working in the sales and distribution of pharmaceutical products for humans and animals and in clinical research.
With research as our main growth engine, developing our laboratories breakthrough medicines for use in diverse areas such as pneumology, cardiology, rheumatology, neurology, virology and oncology. Boehringer Ingelheim also develops products for self-medication and phyto-pharmaceuticals, and a series products for veterinary use. Our activities extend also to the chemical and biopharmaceutical manufacturing. Our main activity in Belgium includes the sale and distribution of pharmaceutical products for humans and animals, as well as clinical research.
Germany and Belgium have long held an important trading relationship, says Margit Kunz of AHK Debelux, the German chamber of commerce in Belgium and Luxembourg. She outlines some of the…
Perhaps to the surprise of many, Belgium is the world’s second-largest producer of vaccines, behind only the US, and – capitalising on its years of experience in the field –…
Back home in Belgium after a stellar stint in Big Pharma, Dr Paul Stoffels is now looking to reshape the future of cancer care with the previously struggling biotech he…
Belgian healthcare performs strongly across most metrics and international comparisons, but – as elsewhere – there remains room for improvement in terms of integrating patient feedback and experience into the…
20-year Astellas veteran Mark Dekker – now back in his home country of the Netherlands and overseeing the Benelux cluster having primarily developed his career in emerging European markets –…
Marnix Denys of beMedTech – the Belgian association for the medical technology industry – outlines the agenda priorities for the organisation that he hopes will lead to a more value-driven…
RaDiOrg aims to support rare disease patients and patient organisations in Belgium, defend their interests, and raise awareness of what can be devastating and little-understood conditions. Director Eva Schoeters –…
The newly merged Port of Antwerp-Bruges is the world’s first GDP-compliant seaport. CCO Tom Hautekiet explains the significant role the Port is playing in global healthcare supply chains – leveraging…
Back home in Belgium after a stellar stint in Big Pharma, Dr Paul Stoffels* is now looking to reshape the future of cancer care with the biotech he helped co-found…
Univercells is a group of companies founded a decade ago based around the concept of revolutionizing the availability of biologics around the world through making essential medicines affordable to all,…
GSK has undergone a number of changes in recent years. After driving a major transformation that began in 2017 to strengthen its R&D performance, the British multinational suffered the impact…
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has elected a new president and vice presidents who have set out a key priority for their term: a series of…
See our Cookie Privacy Policy Here
